Straits Times Index
3,294.62 +28.67 (+0.88%) Nikkei
38,309.25 +235.27 (+0.62%) Hang Seng
18,794.24 +256.43 (+1.38%) FTSE 100
8,381.35 +27.30 (+0.33%) Bitcoin USD
62,909.85 +1,443.15 (+2.35%) CMC Crypto 200
1,352.01 +51.91 (+3.99%)
PFE Sep 2024 22.500 put
| Previous close | 0.1600 |
| Open | 0.1700 |
| Bid | 0.1100 |
| Ask | 0.1400 |
| Strike | 22.50 |
| Expiry date | 2024-09-20 |
| Day's range | 0.1300 - 0.1800 |
| Contract range | N/A |
| Volume | |
| Open interest | 25.24k |
BenzingaSecond Death - Pfizer Reports Young Boy's Death After One Year Of Gene Therapy Treatment In Muscle Wasting Disorder Trial
A young patient died due to cardiac arrest after receiving Pfizer Inc’s (NYSE:PFE) experimental gene therapy in a mid-stage trial for Duchenne muscular dystrophy (DMD), the company told in a letter to Parent Project Muscular Dystrophy. The boy was enrolled in Phase 2 DAYLIGHT study studying the treatment in boys at least two years old and under four years old. The patient received the investigational gene therapy, fordadistrogene movaparvovec (PF-06939926), in early 2023. Citing Pfizer, Reuters
Insider MonkeyOPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK) Q1 2024 Earnings Call Transcript May 7, 2024 OPKO Health, Inc. misses on earnings expectations. Reported EPS is $-0.11577 EPS, expectations were $-0.09. OPKO Health, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and […]
- Reuters
UPDATE 1-Pfizer agrees to settle over 10,000 Zantac lawsuits, Bloomberg News reports
Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug Zantac, Bloomberg News reported on Wednesday, citing people familiar with the deal. The agreements cover cases in U.S. state courts but don't completely resolve the company's exposure to Zantac claims, the report said, adding that financial details of the deals were not immediately available. Pfizer did not immediately respond to a Reuters request for comment.
